Keywords: ph, iii, motesanib, trial, suspended, deaths, enrollment
Ph III motesanib trial suspended on deaths
Article | 01 December 2008
Enrollment in the Phase III MONET1 trial evaluating motesanib (AMG 706) plus paclitaxel and carboplatin for the first-line treatment of advanced, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
